Medicine

Etravirine for HIV-1-infected Patients Failing Antiretroviral Therapy

&t

Margaret Johnson
Margaret Johnson

;em>REFERENCE: Lancet 2007; 370:39-48
MARGARET JOHNSON, Royal Free Hospital, London
A new non-nucleoside reverse-transcriptase inhibitor has demonstrated its activity in patients infected with HIV-1. TMC125, or etravirine, was compared with placebo in over 500 treatment-experienced patients in the DUET-2 trial, and Derek Thorne heard more from Margaret Johnson of the Royal Free Hospital in London.

Similar Interviews

  • Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February

  • DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
  • Pedro Cahn REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007

  • Herpes Simplex Therapy Reduces HIV Activity in Co-Infected Patients
  • PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine REFERENCE: N Engl J Med 2007; 356: 790-9 In patients who are infected

    Post a comment

    Subscribe to Audio Medica Podcast